These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32447435)

  • 1. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry.
    Fernandez-Fernandez C; Lázaro-Bengoa E; Fernández-Antón E; Quiroga-González L; Montero Corominas D
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1175-1181. PubMed ID: 32447435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance.
    Lee I; Jokinen JD; Crawford SY; Calip GS; Kilpatrick RD; Lee TA
    Ther Innov Regul Sci; 2021 Jan; 55(1):142-151. PubMed ID: 32720297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
    Bergvall T; Norén GN; Lindquist M
    Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Completeness of pharmacovigilance reporting in general medicine in France.].
    Humbert X; Jacquot J; Alexandre J; Sassier M; Robin N; Pageot C; Kheloufi F; Joyau C; Coquerel A; Durrieu G; Fedrizzi S
    Sante Publique; 2019; Vol. 31(4):561-566. PubMed ID: 31959257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
    Plessis L; Gómez A; García N; Cereza G; Figueras A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
    Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
    Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis.
    Araujo AGS; Lucchetta RC; Tonin FS; Pontarolo R; Borba HHL; Wiens A
    Expert Opin Drug Saf; 2021 Jun; 20(6):735-740. PubMed ID: 33641547
    [No Abstract]   [Full Text] [Related]  

  • 12. The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase®.
    Matlala MF; Lubbe MS; Steyn H
    Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e9. PubMed ID: 36744452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports.
    Oosterhuis I; Rolfes L; Ekhart C; Muller-Hansma A; Härmark L
    Expert Opin Drug Saf; 2018 Feb; 17(2):111-115. PubMed ID: 29157026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
    Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
    Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient Safety.
    Jokinen J; Bertin D; Donzanti B; Hormbrey J; Simmons V; Li H; Dharmani C; Kracht K; Hilzinger TS; Verdru P
    Ther Innov Regul Sci; 2019 Nov; 53(6):736-745. PubMed ID: 31684774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.